Randomization
colorectal cancer, peritoneal cancer, CRS
COLORECTAL CANCER, PERITONEAL CANCER, METASTASES
Patients were randomized 1:1 to perioperative systemic therapy (experimental arm) or CRS–HIPEC alone (control arm) using minimization stratified by previous systemic therapy for colorectal cancer (yes, no), onset of peritoneal metastases (synchronous, metachronous), peritoneal cancer index (≤ 10, > 10), and planned HIPEC regimen (mitomycin C, oxaliplatin).